A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature

International Journal of Pediatric Endocrinology

Pierre Bougnères¹  Agnès Linglart¹  Anya Rothenbuhler¹ 

[1] Department of Pediatric Endocrinology, Bicêtre Hospital, Pôle I3E, AP-HP, Paris Sud University, 94275 Le Kremlin Bicêtre, France

关键词: End of puberty;    Short children;    Growth hormone;    Anastrozole;    Idiopathic short stature;   

Others  :  1145459
DOI  :  10.1186/1687-9856-2015-4

 received in 2014-08-22, accepted in 2014-12-22,  发布年份 2015

【 摘 要 】

Background

When given during the course of puberty, anastrozole (A), an aromatase inhibitor, has been shown to increase the predicted adult height (PAH) of GH-deficient (GHD) boys treated with recombinant human growth hormone (rhGH). Our study questioned whether this treatment could retain some of its effects in non-GHD adolescent boys if started only at the very end of puberty, a time when rhGH treatment is denied to short adolescents who have almost reached their final height.

Objective

To explore the effect on adult height of a combination of rhGH and A, compared with rhGH alone, at the end of puberty in boys with idiopatic short stature (ISS).

Methods

A prospective randomized study comparing rhGH + A and rhGH was conducted in 24 healthy adolescent boys aged 15.2 ± 1.2 yrs with serum testosterone at adult levels and a faltering growth velocity <3.5 cm/yr leading to a predicted adult height (PAH) <2.5 SDS. Treatments were stopped when growth velocity became <10 mm in 6 months or when height was close to 170 cm. A historical group of ISS adolescents (N = 17) matched for puberty and growth was used for comparison.

Results

IGF1 levels remained within normal limits in all treated patients. Mean treatment duration was 19 months in the rhGH + A group and 11.5 months in the rhGH group (P = 6.10⁻⁴). Adult height reached 168.4 ± 2.6 cm in the rhGH + A group and 164.2 ± 5.6 cm in the rhGH group (P < 0.02). Adult height was 160.1 ± 2.8 cm in the historical controls.

Conclusion

A combination of rhGH and A, started at the very end of puberty, seems to allow boys with ISS to reach a greater adult height than rhGH alone. Larger trials are needed to confirm this preliminary observation.

【 授权许可】

   
2015 Rothenbuhler et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ranke MB: Towards a consensus on the definition of idiopathic short stature. Horm Res 1996, 45(Suppl 2):64-6.
• [2]Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, et al.: Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008, 93:4210-7.
• [3]Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P: Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res 2008, 18(2):89-110.
• [4]Rosenfeld RG, Hwa V: Toward a molecular basis for idiopathic short stature. J Clin Endocrinol Metab 2004, 89(3):1066-7.
• [5]Wit JM, Kamp GA, Rikken B: Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Pediatr Res 1996, 39:295-302.
• [6]Rekers-Mombarg LT, Wit JM, Massa GG, Ranke MB, Buckler JM, Butenandt O, et al.: Spontaneous growth in idiopathic short stature. European Study Group Arch Dis Child 1996, 75(3):175-80.
• [7]Wit JM: Idiopathic short stature: reflections on its definition and spontaneous growth. Horm Res 2007, 67(Suppl 1):50-7.
• [8]Price DA: Spontaneous adult height in patients with idiopathic short stature. Horm Res 1996, 45(Suppl 2):59-63.
• [9]Ranke MB, Grauer ML, Kistner K, Blum WF, Wollmann HA: Spontaneous adult height in idiopathic short stature. Horm Res 1995, 44(4):152-7.
• [10]Leschek EW, Rose SR, Yanovski JA, Troendle JF, Quigley CA, Chipman JJ, et al.: Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004, 89(7):3140-8.
• [11]McCaughey ES, Mulligan J, Voss LD, Betts PR: Randomised trial of growth hormone in short normal girls. Lancet 1998, 351(9107):940-4.
• [12]Albertsson-Wikland K, Aronson AS, Gustafsson J, Hagenäs L, Ivarsson SA, Jonsson B, et al.: Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab 2008, 93(11):4342-50.
• [13]López-Siguero JP, García-Garcia E, Carralero I, Martínez-Aedo MJ: Adult height in children with idiopathic short stature treated with growth hormone. J Pediatr Endocrinol Metab 2000, 13(9):1595-1602.
• [14]Coutant R, Rouleau S, Despert F, Magontier N, Loisel D, Limal JM: Growth and adult height in GH-treated children with nonacquired GH deficiency and idiopathic short stature: the influence of pituitary magnetic resonance imaging findings. J Clin Endocrinol Metab 2001, 86(10):4649-54.
• [15]Lopez-Siquero JP, Martínez-Aedo MJ, Moreno-Molina JA: Final height after growth hormone therapy in children with idiopathic short stature and a subnormal growth velocity. Acta Pediatr 1996, 85:113-47.
• [16]Hindmarsh PC, Brook CG: Final height of short normal children treated with growth hormone. Lancet 1996, 348(9019):13-6.
• [17]Wit JM, Rekers-Mombarg LT, Dutch Growth Hormone Advisory Group: Final height gain by GH therapy in children with idiopathic short stature is dose dependent. J Clin Endocrinol Metab 2002, 87(2):604-11.
• [18]Buchlis JG, Irizarry L, Crotzer BC, Shine BJ, Allen L, MacGillivray MH: Comparison of final heights of growth hormone-treated vs. untreated children with idiopathic growth failure. The Journal of Clinical Endocrinology & Metabolism 1998, 83(4):1075-9.
• [19]Christensen TL, Djurhuus CB, Clayton P, Christiansen JS: An evaluation of the relationship between adult height and health-related quality of life in the general UK population. Clin Endocrinol (Oxf) 2007, 67:407-12.
• [20]Coste J, Pouchot J, Carel JC: Height and health-related quality of life: a nationwide population study. J Clin Endocrinol Metab 2012, 97:3231-9.
• [21]Theunissen NC, Kamp GA, Koopman HM, Zwinderman KA, Vogels T, Wit JM: Quality of life and self-esteem in children treated for idiopathic short stature. J Pediatr 2002, 140(5):507-15.
• [22]Radcliffe DJ, Pliskin JS, Silvers JB, Cuttler L: Growth hormone therapy and quality of life in adults and children. Pharmacoeconomics 2004, 22:499-524.
• [23]Sandberg DE, Brook AE, Campos SP: Short stature: a psychosocial burden requiring growth hormone therapy? Pediatrics 1994, 94:832-40.
• [24]Bullinger M: Psychological criteria for treating children with idiopathic short stature. Horm Res Paediatr 2011, 76(Suppl 3):20-3.
• [25]Chaplin JE: Growth-related quality of life. Horm Res Paediatr 2011, 76(Suppl 3):51-2.
• [26]Dunkel L, Wit JM: Developments in idiopathic short stature. Horm Res Paediatr 2011, 76(Suppl 3):1-60.
• [27]Noeker M: Psychological functioning in idiopathic short stature. Horm Res Paediatr 2011, 76(Suppl 3):52-6.
• [28]Rekers-Mombarg LT, Busschbach JJ, Massa GG, Dicke J, Wit JM: Quality of life of young adults with idiopathic short stature: effect of growth hormone treatment. Dutch Growth Hormone Working Group Acta Paediatr 1998, 87(8):865-70.
• [29]Sandberg DE: Psychosocial aspects of short stature and its management: good deeds require good science. Horm Res Paediatr 2011, 76(Suppl 3):37-9.
• [30]Sandberg DE, Bukowski WM, Fung CM, Noll RB: Height and social adjustment: are extremes a cause for concern and action? Pediatrics 2004, 114(3):744-50.
• [31]Rosenbloom AL: Idiopathic short stature: conundrums of definition and treatment. Int J Pediatr Endocrinol 2009., 470378
• [32]Voss LD: Growth hormone therapy for the short normal child: who needs it and who wants it? The case against growth hormone therapy. J Pediatr 2000, 136(1):103-6.
• [33]Ambler GR, Fairchild J, Wilkinson DJ: Debate: idiopathic short stature should be treated with growth hormone. J Paediatr Child Health 2013, 49(3):165-9.
• [34]Guyda HJ: Four decades of growth hormone therapy for short children: what have we achieved? J Clin Endocrinol Metab 1999, 84(12):4307-16.
• [35]Rosenbloom AL: Pediatric endo-cosmetology and the evolution of growth diagnosis and treatment. J Pediatr 2011, 158(2):187-93.
• [36]Collett-Solberg PF: Update in growth hormone therapy of children. J Clin Endocrinol Metab 2011, 96:573-9.
• [37]Ranke MB: Treatment of children and adolescents with idiopathic short stature. Nat Rev Endocrinol 2013, 9:325-34.
• [38]Finkelstein BS, Imperiale TF, Speroff T, Marrero U, Radcliffe DJ, Cuttler L: Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis. Arch Pediatr Adolesc Med 2002, 156:230-40.
• [39]Bryant J, Baxter L, Cave CB, Milne R: Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev 2007, CD004440.
• [40]Deodati A, Peschiaroli E, Cianfarani S: Review of growth hormone randomized controlled trials in children with idiopathic short stature. Horm Res Paediatr 2011, 76(Suppl 3):40-2.
• [41]Sotos JF, Tokar NJ: Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit. Int J Pediatr Endocrinol 2014, 2014(1):15. BioMed Central Full Text
• [42]Loche S, Cambiaso P, Setzu S, Carta D, Marini R, Borrelli P, et al.: Final height after growth hormone therapy in non-growth-hormone-deficient children with short stature. J Pediatr 125:196-2000.
• [43]Wit JM, Rekers-Mombarg LT, Cutler GB, Crowe B, Beck TJ, Roberts K, et al.: Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. J Pediatr 2005, 146:45-53.
• [44]Hintz RL, Attie KM, Baptista J, Roche A: Effect of growth hormone treatment on adult height of children with idiopathic short stature. Genentech Collaborative Group N Engl J Med 1999, 340:502-7.
• [45]Lee PA, Savendahl L, Oliver I, Tauber M, Blankenstein O, Ross J, et al.: Comparison of response to 2-years’ growth hormone treatment in children with isolated growth hormone deficiency, born small for gestational age, idiopathic short stature, or multiple pituitary hormone deficiency: combined results from two large observational studies. Int J Pediatr Endocrinol 2012, 2012:22. BioMed Central Full Text
• [46]Dahlgren J: Growth outcomes in individuals with idiopathic short stature treated with growth hormone therapy. Horm Res Paediatr 2011, 76(Suppl 3):42-5.
• [47]Hopwood NJ, Hintz RL, Gertner JM, Attie KM, Johanson AJ, Baptista J, et al.: Growth response of children with non-growth-hormone deficiency and marked short stature during three years of growth hormone therapy. 1993. J Pediatr 1994, 123:215-22.
• [48]Hughes IP, Harris M, Choong CS, Ambler G, Cutfield W, Hofman P, et al.: Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature. Clin Endocrinol (Oxf) 2012, 77:62-71.
• [49]Van Gool SA, Kamp GA, Odink RJ, de Muinck Keizer-Schrama SM, de Waal HA D-v, Oostdijk W, et al.: High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height. Eur J Endocrinol 2010, 162:653-60.
• [50]Cohen P, Germak J, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG: Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J Clin Endocrinol Metab 2010, 95:2089-98.
• [51]Cohen P, Weng W, Rogol AD, Rosenfeld RG, Kappelgaard AM, Germak J: Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations. Clin Endocrinol (Oxf) 2014.
• [52]Cohen P, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG, Germak J: Efficacy of IGF-based growth hormone (GH) dosing in nonGH-deficient (nonGHD) short stature children with low IGF-I is not related to basal IGF-I levels. Clin Endocrinol (Oxf) 2013, 78:405-14.
• [53]Roche AF: The final phase of growth in stature. Growth, Genetics and Hormones 1989, 5:4-6.
• [54]Roche AF: Growth, Maturation and Body Composition. The Fels Longitudinal Study 1929–1991. Press CU; 1992. 104–106 and 132–138
• [55]Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976, 51:170-9.
• [56]Tanner JM, Whitehouse RH, Marubini E, Resele LF: The adolescent growth spurt of boys and girls of the Harpenden growth study. Ann Hum Biol 1976, 3:109-26.
• [57]Wit JM, Hero M, Nunez SB: Aromatase inhibitors in pediatrics. Nat Rev Endocrinol 2011, 8:135-47.
• [58]Dunkel L: Update on the role of aromatase inhibitors in growth disorders. Horm Res 2009, 71(Suppl 1):57-63.
• [59]Dunkel L: Use of aromatase inhibitors to increase final height. Mol Cell Endocrinol 2006, 254–255:207-16.
• [60]Shulman DI, Francis GL, Palmert MR, Eugster EA: Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Pediatrics 2008, 121:e975-83.
• [61]Mauras N: Strategies for maximizing growth in puberty in children with short stature. Endocrinol Metab Clin North Am 2009, 38:613-24.
• [62]Dunkel L: Off-label use of aromatase inhibitors to promote taller stature: is it safe. Horm Res Paediatr 2010, 74:436-7.
• [63]Dunkel L: Treatment of idiopathic short stature: effects of gonadotropin-releasing hormone analogs, aromatase inhibitors and anabolic steroids. Horm Res Paediatr 2011, 76(Suppl 3):27-9.
• [64]Diaz-Thomas A, Shulman D: Use of aromatase inhibitors in children and adolescents: what’s new? Curr Opin Pediatr 2010, 22:501-7.
• [65]Geffner ME: For debate: Aromatase inhibitors to augment height: have we lost our inhibitions? Pediatr Endocrinol Rev 2008, 5:756-9.
• [66]Geffner ME: Aromatase inhibitors to augment height: continued caution and study required. J Clin Res Pediatr Endocrinol 2009, 1:256-61.
• [67]Wickman S, Sipilä I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L: A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001, 357:1743-8.
• [68]Hero M, Norjavaara E, Dunkel L: Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005, 90:6396-402.
• [69]Hero M, Wickman S, Dunkel L: Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 2006, 64:510-3.
• [70]Salehpour S, Alipour P, Razzaghy-Azar M, Ardeshirpour L, Shamshiri A, Monfared MF, et al.: A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature. Horm Res Paediatr 2010, 74:428-35.
• [71]Hero M, Toiviainen-Salo S, Wickman S, Mäkitie O, Dunkel L: Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty. J Bone Miner Res 2010, 25:1536-43.
• [72]Mauras N, Welch S, Rini A, Klein KO: An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol Metab 2004, 17:1597-606.
• [73]Mauras N, Gonzalez de Pijem L, Hsiang HY, Desrosiers P, Rapaport R, Schwartz ID, et al.: Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008, 93:823-31.
• [74]Vincelet C, Tabone MD, Berthier M, Bonnefoi MC, Chevallier B, Lemaire JP, et al.: Le carnet de santé de l’enfant est-il informatif? Évaluation dans différentes structures de prévention et de soins. Arch Pediatr 2003, 10(5):403-9.
• [75]Greulich WaP S: Radiographic Atlas of Skeletal Development of Hand and Wrist. Stanford University Press; 1959.
• [76]O’Connor JE, Bogue C, Spence LD, Last J: A method to establish the relationship between chronological age and stage of union from radiographic assessment of epiphyseal fusion at the knee: an Irish population study. J Anat 2008, 212:198-209.
• [77]Roche AF, Wainer H, Thissen D: The Knee Joint as a Biological Indicator. New York: Plenum Press; 1975.
• [78]Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG: Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007, 92:2480-6.
• [79]Garn SM, Rohman CG, Apfelbaum B: Complete epiphyseal union of the hand. Am J Phys Anthropol 1961, 19:365-72.
• [80]Shams K, Cameo T, Fennoy I, Hassoun AA, Lerner SE, Aranoff GS, et al.: Outcome analysis of aromatase inhibitor therapy to increase adult height in males with predicted short adult stature and/or rapid pubertal progress: a retrospective chart review. J Pediatr Endocrinol Metab 2014, 27(7–8):725-30.
• [81]Durand-Zaleski I: Developments in idiopathic short stature: cost versus allocation of resources. Horm Res Paediatr 2011, 76(Suppl 3):33-5.
• [82]Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B: Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010, 95:167-77.
• [83]Quigley CA, Gill AM, Crowe BJ, Robling K, Chipman JJ, Rose SR, et al.: Safety of growth hormone treatment in pediatric patients with idiopathic short stature. J Clin Endocrinol Metab 2005, 90(9):5188-96.
• [84]Rosenfeld RG, Cohen P, Robison LL, Bercu BB, Clayton P, Hoffman AR, et al.: Long-term surveillance of growth hormone therapy. J Clin Endocrinol Metab 2012, 97(1):68-72.
• [85]Kemp SF, Kuntze J, Attie KM, Maneatis T, Butler S, Frane J, et al.: Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab 2005, 90(9):5247-53.
• [86]Savendahl L, Maes M, Albertsson-Wikland K, Borgstrom B, Carel JC, Henrard S, et al.: Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab 2012, 97:E213-7.
• [87]De Ronde W, de Jong FH: Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol 2011, 9:93. BioMed Central Full Text
• [88]Raven G, de Jong FH, Kaufman JM, de Ronde W: In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin Endocrinol Metab 2006, 91:3324-8.
• [89]T’Sjoen GG, Giagulli VA, Delva H, Crabbe P, De Bacquer D, Kaufman JM: Comparative assessment in young and elderly men of the gonadotropin response to aromatase inhibition. J Clin Endocrinol Metab 2005, 90:5717-22.
• [90]Hero M, Ankarberg-Lindgren C, Taskinen MR, Dunkel L: Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. Eur J Endocrinol 2006, 155:453-60.
• [91]Jolliffe CJ, Janssen I: Distribution of lipoproteins by age and gender in adolescents. Circulation 2006, 114:1056-62.
• [92]Wickman S, Kajantie E, Dunkel L: Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocrinol Metab 2003, 88:3785-93.
• [93]Hero M, Makitie O, Kroger H, Nousiainen E, Toiviainen-Salo S, Dunkel L: Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Horm Res 2009, 71:290-7.